Mylan Recalls Paliperidone Extended-Release Tablets Due to Dissolution Failures
Mylan Pharmaceuticals is recalling 2,928 bottles of Paliperidone Extended-Release Tablets, 1.5 mg, because they failed dissolution specifications at a three-month stability time point.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically corresponds to a Moderate severity score when no specific injuries or hospitalizations are reported in the source text, and the defect is a stability/dissolution failure rather than a high-risk pathogen or structural defect.
Plain-English summary
Mylan Pharmaceuticals, Inc. is voluntarily recalling 2,928 bottles of Paliperidone Extended-Release Tablets, 1.5 mg, 30-count bottles. The product is identified by NDC 0378-3978-93, Lot 2005441, and an expiration date of 01/2017. The recall is being conducted because the tablets failed to meet dissolution specifications at a three-month stability time point.
The affected product was distributed nationwide. Paliperidone Extended-Release Tablets are prescription-only medications. The recall is classified as Class II by the U.S. Food and Drug Administration, indicating that use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Consumers and healthcare providers who have this specific lot of Paliperidone Extended-Release Tablets should stop using them and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The recall is limited to the specific lot and NDC number listed above.
The recalled product
- Product
- Paliperidone Extended-release Tablets, 1.5 mg, 30 count bottles, Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV --- NDC 0378-3978-93
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Antipsychotic
- Affected units
- 2,928
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot: 2005441
- 01/2017
- Code: 0378-3978-93
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
- HighPrasugrel 5 mg Tablets Recalled Due to Failed Dissolution Specifications
FDA (Drugs) · 2025-03-26
- CriticalInsulin Glargine Prefilled Pens Recalled for Missing Label
FDA (Drugs) · 2022-08-03
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17
- ModerateBelsomra 10 mg tablets failed dissolution, which may delay sleep onset
FDA (Drugs) · 2025-08-20